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1. Introduction 
Chemokines are small low molecular weight proteins or cytokines secreted by cells that 
function as chemical messengers. They were originally found to attract leukocytes to site(s) 
of inflammation. As ligands they activate and signal through their respective chemokine 
receptors triggering an influx of intracellular calcium (Ca2+) ions causing a process known 
as chemotaxis. Chemokine receptors are integral membrane proteins that specifically bind 
and respond to chemokines. They are members of the class A subfamily of G-protein 
coupled receptor (GPCRs) superfamily, a name derived from the characteristic cysteine 
motif of the group of chemokines they interact with. Despite their pivotal roles in the 
immune system and angiogenesis, chemokines as well as their receptors have been 
associated with a number of pathologies including autoimmune disorders, pulmonary 
diseases, transplant rejection, cancers, vascular diseases and human immunodeficiency 
virus (HIV) infection. Scientists have noted that while the CD4 receptor is necessary for the 
successful infection of host immune cells by all naturally occurring HIV-1 strains it is not 
sufficient. Thus, another specific cell surface molecule called chemokine receptor is 
required. The recent introduction of entry inhibitors in the clinic as components of 
antiretroviral treatment has increased the research interest of coreceptor usage in HIV 
infection. Chemokine receptors are subjects of significant medical importance which not 
only provide new insights into the mechanisms of viral entry, tropism and pathogenesis, 
but have also culminated into new control strategies from the host’s perspective 
influencing HIV transmission along with disease progression. Identification of the different 
phenotypes of HIV-1 strains with different prevalence during various stages of disease 
progression and the role of these phenotypes in treatment outcome has further 
revolutionalised research in this field. This chapter seeks to depict a simple and clear 
understanding of the basics of HIV phenotypes or genotypes and the respective current as 
well as prospective diagnostic tools. Milestones and challenges in this relatively new class 
of antiretroviral therapy of coreceptor antagonists will also be highlighted.  
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2. Structure of chemokine receptors 
Chemokine receptors consist of about 350 amino acids that are divided into a short and 
acidic N-terminal end, seven helical transmembrane domains since they span the cell 
membrane seven times with three intracellular and three extracellular hydrophilic loops, 
and an intracellular C-terminus containing serine and threonine residues that act as 
phosphorylation sites during receptor regulation as shown in Figure 1 below. Chemokine 
receptors are usually linked to a G-protein through which they signal. The N-terminus of 
the chemokine receptor is an extracellular domain that binds the chemokine(s) and has been 
shown to influence infection tropism. The first two extracellular loops of chemokine 
receptors are linked together by disulphide bonding between two conserved cysteine 
residues. The disulfide bonds keep the extracellular loops in place thereby maintaining the 
structural integrity necessary for ligand binding and signal transduction. In spite of the high 
amino acid similarity of their primary sequences, chemokine receptors bind a limited 
number of ligands. 
 
Figure 1. Typical structure of a chemokine receptor  
3. Classification of chemokine receptors 
To date, approximately 50 human chemokines and 20 receptors have been discovered. 
Basically chemokines and their receptors are divided into four subfamilies; CXC, CC, CX3C 
and XC depending on the position of the two pairs of the highly conserved cysteine residues 
on the ligands, where C denotes the cysteine amino acid residue whilst X represents non-
cysteine amino acids. For the main subfamilies, the first two cysteines are either contiguous 
(CC) or intercalated by one non cysteine amino acid residue (CXC). A system of 
nomenclature has been introduced where each ligand and receptor is identified by its 
subfamily and an identifying number. For example, CCL2 refers to a chemokine ligand of 
the CC subfamily, number 2. Similarly, the receptors are referred to by subfamily R and 
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similarly an identifying number. Thus, for instance one of the receptors of CCL5 is called 
CCR5. Despite the numerous chemokine receptors that are prospective coreceptors for HIV 
in vitro, only CCR5 and CXCR4 have attracted substantial interest because they form portals 
of cellular entry for both HIV-1 and HIV-2 inclusive of other related simian or feline 
retroviruses. The lack of crystallography for these two highly hydrophobic coreceptors 
makes them difficult to isolate.  
4. CXC chemokine receptors 
The first HIV coreceptor to be identified was CXCR4 which was originally an orphan 
receptor called leukocyte-derived seven-transmembrane domain receptor (LESTR). By then 
it did not receive much attention until it was recognized as a coreceptor for HIV-1. Thus, in 
the mid 1990s the second receptor, CXCR4, needed for successful entry of HIV into cells was 
discovered. At that time this coreceptor was termed “fusin” as it facilitated certain HIV 
strains to fuse with and enter immune cells called T cells. A detailed analysis of the structure 
of fusin revealed that it was a receptor for chemokines which were previously shown to 
suppress HIV activity. CXCR4 has a wide cellular distribution. It is commonly expressed on 
most immature and mature hematopoietic cell types, cells of the central nervous system, 
neutrophils, monocytes, T and B cells, dendritic cells (DCs), Langerhans cells and 
macrophages. To date there are seven CXC chemokine receptors in mammals, named 
CXCR1 through CXCR7. The CXC chemokines include stromal cell-derived factor-1 alpha 
and beta now officially designated CXCL12a and CXCL12b respectively. CXCL12 is often 
induced by pro-inflammatory stimuli such as lipopolysaccharide, interleukin-1 (IL-1) or 
tumour necrosis factor-alpha (TNF-α) and has been shown to be strongly chemotactic for 
lymphocytes. Its high level of expression in the genital mucosa may help to explain the 
inefficient transmission of CXCR4-tropic HIV isolates. 
5. CC chemokine receptors 
Another chemokine receptor necessary for the entry of HIV into macrophages called CCR5 
that was subsequently identified. CCR5 receptors have been shown to be involved in 
leukocyte activation and mobilization. CCR5 is expressed on several cell types including 
peripheral blood-derived DCs, CD34+ hematopoietic progenitor cells and some 
activated/memory Th1 lymphocyte. Chemokines that bind these receptors are RANTES 
(regulated-upon-activation normal T expressed and secreted); MIP-1α and MIP-1β 
(macrophage inflammatory protein-1 alpha and beta) previously observed to suppress HIV 
infection but now officially called CCL5, CCL3 and CCL4 respectively. In vitro studies have 
demonstrated several CC chemokines bind CCR5. However, CCL3, CCL4, CCL5, and CCL8 
have shown the most suppressive effects in HIV-1 infection assays. To date ten members of 
the CC chemokine receptor subfamily have been described, namely CCR1 through to CCR10 
according to the IUIS/WHO Subcommittee on Chemokine Nomenclature. CCR5 is one of the 
major coreceptor implicated in susceptibility to HIV-1 infection and disease progression. 
The lack of CCR5 gene expression has been associated with resistant to HIV-1 infection as 
will be discussed later on.  
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6. CX3CR1 
CX3C chemokine receptor 1 (CX3CR1) also known as the fractalkine receptor or G-protein 
coupled receptor 13 (GPR13) has been shown to bind chemokine CX3CL1, also called 
fractalkine. Fractalkine is a transmembrane chemokine involved in the adhesion and 
migration of leukocytes. CX3CR1 is expressed on monocytes and plays a major role in the 
survival of monocytes. It has been shown to interact with human respiratory syncytial virus 
protein G consequently, modulating the host immune response. It also interacts with HIV-1 
envelope (env) polyprotein glycoprotein (gp) 160. Thus CX3CR1 is also a minor coreceptor 
for HIV-1. Certain variations in the expression this gene has been associated with increased 
susceptibility to HIV-1 infection and rapid progression to AIDS.  
7. XCR1 
The "C" sub-family of chemokine receptors contains only one member: XCR1, also known as 
GPR5. It is the receptor for chemokines XCL1 and XCL2 formerly, lymphotactin-1 and-2, 
respectively. This receptor is closely related to the MIP-1 α and RANTES yet to date its 
expression and the function of its ligand XCL1 remain elusive. However, at least in murine 
models, XCR1 has been shown to be expressed on CD8+ DCs and that its ligand XCL1 has 
shown to be a potent and highly specific chemo-attractant for this subset of DCs.  
8. Tropism 
HIV-1 was initially isolated from peripheral blood cells and consequently characterised as a 
virus that infects the CD4+ T-lymphocyte population, T tropic isolates. However, 
subsequent isolation of HIV-1 from non-lymphoid organs demonstrated that HIV-1 could 
also infect cells of the monocyte-macrophage lineage; macrophage tropic isolates. Studies 
have shown that T-cell and macrophage isolates display significant different biological 
properties with respect to cellular tropism, genetic diversity and relative replication rates 
including their inherent ability to induce syncytia. 
9. MT-2 cell tropism 
Biological differences of HIV-1 isolates and depletion of CD4 positive lymphocytes have 
been shown to correlate with the pathogenesis of AIDS. Direct cytopathic effects of HIV can 
be studied in vitro in T cell lines. An MT-2 tumour cell line assay is generally used for the 
phenotypic characterisation of HIV-1 isolates. The ability of HIV-1 isolates to replicate in 
MT-2 cell lines is a prototype where viruses that do not infect MT-2 cells are designated non-
syncytium inducing (NSI), while those that infect cells are termed syncytium inducing (SI). 
Studies have shown that HIV-1 isolates from patients with low CD4 counts have been 
shown to replicate rapidly to high titres in peripheral blood mononuclear cells (PBMCs) 
with the infected cells forming syncytia and such isolates are called rapid/high replicating or 
syncytium inducing (SI). HIV-1 isolates from asymptomatic individuals replicate much 
slowly with low titres and such isolates are termed slow/low or NSI. Consequently, HIV-1 
isolates can be classified into two main groups; those that replicate in T–cell lines, grow 
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rapidly in cultures forming syncytia in target cells and the other group that replicate in 
macrophages, grow relatively slowly in culture but are not able to induce syncytia, SI and 
NSI, respectively. The formation of syncytia does not always happen in HIV infected people. 
However, autopsies have found syncytia in the spleens of some patients. More frequently 
CD4 syncytia have been observed in the brains of patients who would have died from 
serious AIDS related neurological complications.  
10. HIV strains classification based on tropism 
Following the identification of the coreceptors, HIV-1 isolates have also been characterized 
based on their ability to infect and induce syncytia in CD4+ T-cell lines that express CXCR4 
but not CCR5.While all the HIV-1 strains require CD4 to enter and infect cells, some isolates 
utilize the chemokine receptors X4 or R5 while other variants use both receptors, dual tropic 
(R5X4) strains for binding and entry. Coreceptor usages correspond to the phenotypes 
previously defined by the MT-2 assay with SI and NSI viruses using CXCR4 and CCR5, 
respectively. Dual tropic isolates exhibit both the M and T tropic characteristics. They are 
further classified as dual-R; R5X4 variants with more efficient use of CCR5 than of CXCR4 
or dual-X; R5X4 with more efficient use of CXCR4 than of CCR5. In vitro studies have shown 
that some HIV-1 strains can use a variety of other chemokine receptors. Interestingly, this 
does not appear to have major relevance to HIV infection nor pathogenesis in vivo. MT-2 
positive variants are defined as either X4 or R5X4. Absence of viral growth in this assay may 
be either due to the exclusive presence of R5 variants or failure to isolate HIV. 
Frequencies of R5 HIV-1 variants vary among different populations, being 80% and 50% in 
drug naïve individuals and patients receiving antiretroviral therapy, respectively. Tropism 
shifts have been associated with long term use of antiretroviral therapy. Some studies have 
shown that drug selection pressure may gradually select for pre-existing X4 virus from 
cellular reservoirs during sustained highly active antiretroviral therapy. Thus, the use of 
CCR5 coreceptor antagonists is associated with a selective pressure that promotes the 
emergence of CXCR4-using variants. 
11. Evolution of X4 viruses 
There are different theories regarding the origin of X4 viruses. One theory postulates that X4 
viruses emerge directly from the pre-existing R5 pool as a result of mutations within the 
HIV V3 loop env gene. At least for HIV-1 subtype C, X4 variants have been associated with 
an amino acid substitution mutation from the conserved GPGQ crown motif to a GPGR. Still 
some authors argue that X4 viruses are already in the existing pool of viruses but somehow 
the X4 viruses and R5/X4 viruses remain suppressed by varied host mechanisms and only to 
be detected in the late phases of infection suggestive that the immune system exerts a 
selective pressure that hinders the emergence of CXCR4-using variants. However, when the 
host immune competence begins to deteriorate during the HIV disease progression, it paves 
way for the emergence of CXCR4-using variants. Another hypothesis proposes that 
chemokines and the C2-V3-C3 region of HIV gp120 have a common origin such that the HIV 
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ancestor incorporated a chemokine gene into its env gene such that this captured chemokine 
gene rapidly diverge by frequent mutations thereby attaining the ability to effectively 
interact with various chemokine receptors in a short period of time. Another possible 
explanation is based on cell division rate where it has been observed that X4 and R5 viruses 
show preferential tropism for naive and memory T cells, respectively. Since memory T cells 
divide 10 times more frequently than naive cells, it would be an advantage to have a tropism 
for CCR5 coreceptor during the first stages of infection.  
 
Figure 2. HIV classification adopted from Moyle G, 2008. 
12. Coreceptor usage in HIV-2  
Studies have shown that the use of coreceptors is much broader in HIV-2 infections relative 
to HIV-1. In addition to CCR5 and CXCR4 HIV-2 is able to utilise alternative coreceptors 
such as GPR15, or CXCR6 and to a lesser extent CCR1, CCR2b or CCR3 in aviremic patients 
whilst CXCR4 is only used in viremic individuals. It still needs to be explored whether this 
wide use of coreceptors is the underlying reason behind the less virulent phenotype 
associated with HIV-2, compared to HIV-1.  
13. Clinical application of tropism 
One property that has been closely correlated with clinical prognosis is the ability to induce 
syncytia formation in susceptible cells with clinical course of AIDS being associated with a 
shift from NSI to SI. HIV isolates obtained during early acute infection are generally M- 
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tropic/NSI whilst T-tropic/ SI are associated with disease progression. The emergence of 
CXCR4-using HIV-1 variants in a patient is almost invariably associated with a subsequent 
increase in the rate of decline of circulating CD4+ T cells, an accelerated disease progression 
and a poor prognosis for survival. While CXCR4-using variants can emerge at any stage of 
infection, untreated individuals who develop such variants progress to AIDS within an 
average of two years after their first detection. However, the presence of CXCR4-using 
variants is not an obligatory prerequisite for disease progression as a significant proportion 
of individuals’ progress to AIDS whilst harbouring exclusive R5 HIV-1 variants. The 
emergence of SI HIV-1 in a sero-positive individual is now generally regarded as a negative 
prognostic indicator and thus considerable interest has been focused on the HIV-1 genetic 
determinants of the SI phenotype. Tropism assays are important for determining HIV 
phenotype before administering coreceptor antagonists in combination antiretroviral 
therapy. In view of this, tropism assays must taken by HIV infected people with drug 
resistance who are considering taking coreceptor antagonists. This new class of anti-
retroviral targets CCR5-specific HIV during entry into the cell. Thus, knowing the patient’s 
viral tropism can assist and guide the clinician make an informed and effective HIV 
treatment plan. Consequently, the importance of tropism screening to detect the presence of 
R5-using HIV may not be over emphasized. 
14. Methods for determination of coreceptor usage 
With the recent introduction of HIV-1 chemokine receptor antagonists on the market as 
components of antiretroviral therapy, it is increasingly important to screen HIV patients’ 
coreceptor phenotype or genotype prior to therapy. Hence simple and efficient methods 
for routinely characterising and monitoring HIV-1 coreceptor phenotypes or genotypes 
are of paramount importance. Studies have demonstrated that the ability to induce 
syncytia is determined by regions of env outside the V3 loop that encompass residues that 
contribute to the binding of CD4 by gp120. Such observations suggest that areas of the 
HIV-1 env gene contributing to the CD4 binding site may also contribute to the 
determination of SI and NSI genotypes. HIV-1 tropism can be determined by phenotypic 
or genotypic based methods.  
15. Phenotypic methods 
HIV-1 tropism can be assessed using phenotypic assays which are currently the most 
accurate method based on recombinant viruses. Determination of coreceptor use of HIV-1 
isolates is done in cell lines such as U87 and GHOST transfected with CCR5 or CXCR4. 
Patients’ plasma is used to generate pseudoviruses or infectious recombinant viruses of full-
length or partial viral envelopes derived from the patient's viral population. The 
recombinants are subsequently tested on indicator cell lines expressing CD4 and either 
CCR5 or CXCR4. The first commercially available tropism assay became available on the 
market almost at the same time of approval of the CCR5 antagonist, maraviroc. Its brand 
name of phenotypic assay is Trofile® manufactured by Monogram Biosciences South San 
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Francisco, USA. The test can detect 10% of X4 variants with 100% sensitivity. More recently, 
an enhanced Trofile® assay with better sensitivity to improve detection of low level X4-using 
variants has been developed that can detect 0.3% of these variants with 100% sensitivity. 
Trofile® phenotypic assay continues to be the only clinically validated assay to identify 
coreceptor tropism and is considered the gold standard for tropism testing capable of 
distinguishing pure R5, D/M and pure X4 populations.  
Another phenotypic tropism assay, Phenoscript-tropism; Eurofins is also on the market. It 
was specifically developed to cater for phenotypic test for the evaluation of viral tropism in 
HIV-1 non-B subtypes. It is worthwhile to appreciate that the HIV-1 env V3 loop is 
implicated in the determination of phenotypic tropisms  
16. Challenges of phenotypic methods 
Despite having high sensitivity phenotypic assays are laborious, expensive, and time-
consuming and can only be done in sophisticated laboratories by highly qualified 
personnel. More so the presence of CXCR4 viruses, which frequently constitute less than 
5% of viral population is a challenge as phenotypic assays’ sensitivity does not seem to 
permit this range of detection threshold. Consequently, individuals may be misdiagnosed 
as harboring only CCR5 coreceptor using virus, when in actual fact they may also be 
harbouring R4 virus in very low quantities such that once initiated on CCR5 coreceptor 
antagonists their CXCR4 tropic viruses may emerge. Due to the foregoing bottlenecks 
there is need for the development of simple, more sensitive, accurate and less expensive 
tests with a shorter turnaround time to replace slow and resource intensive phenotypic 
assays.  
17. Genotypic coreceptor analysis methods 
HIV env gp120 is composed of about 400 amino acids which consists five relatively 
conserved constant (C1-C5) and five hyper-variable regions (V1-V5). The genetic 
determinants of HIV-1 coreceptor usage are localized in the V3 loop of gp120 which has a 
highly conserved crown motif and glycosylation sites. The third variable region also called 
the V3 loop is composed of 31-39 amino acids. . The V3 loop is closed by a disulfide bridge 
formed by two cysteines. Functionally it is critical in maintaining the right conformation to 
facilitate coreceptor interaction with the virus. This region has been shown to be the major 
determinant of viral tropism and accordingly, prediction of coreceptor usage based on the 
interpretation of V3 sequences using bioinformatics tools could be a good alternative to 
infer tropism in the clinical routine Sequences in the N-terminus of V3 loop have been 
shown to modulate the levels of infection through CCR5 coreceptor. Minor or a few 
sequence alterations or mutations in V3 are sufficient to switch coreceptor use from CCR5 
to CXCR4 or from dual-tropic to X4-tropic virus. Additional mutations within the V1/V2 
have also been observed during coreceptor switching. Studies have shown that such 
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mutations seem to compensate for the harmful V3 mutations. Functional studies have 
demonstrated that the V3 loop interacts with the N-terminal extra-cellular domain of CCR5 
and the extracellular loop 2. Bioinformatics tools based on V3 sequences can be used to 
predict HIV-1 tropism. The identification of viral genotypic changes associated with 
different coreceptor usage has led to the development of sequence-based algorithms to 
predict coreceptor usage. Different rules have been published based on the amino acid 
sequence of the env V3 region of HIV-gp120, which is known to be the major determinant 
of coreceptor usage.  
18. Predictive algorithms of HIV-1 coreceptor usage 
At least eight different bioinformatics tools have been used to predict viral tropism in 
different HIV-1 subtypes which uses phenotypic data to predict the corresponding viral 
genotype. Studies of genotypic predictors have been retrospective with patient samples 
selected based on availability of phenotypic tropism determinations. Three of the 
interpretation systems namely, WetCat, WebPSSM, geno2pheno [coreceptor] are freely 
available on internet. All three focus on the env-V3 region and only take the amino acid 
sequence into account. Such genotypic systems provide the possibility for rapid 
screening of patients who may be administered with CCR5 blockers like maraviroc. On 
cloned viruses belonging to genetic subtype B, the specificity and sensitivity of most 
predictive methods exceed 90% and 80%, respectively. While genotypic assays may have 
lower specificity and sensitivity, retrospective analyses have found that they are 
comparable to phenotypic tropism assays for prediction of response to treatment with 
CCR5 antagonists in populations pre-screened with a phenotypic assay. The first 
genotypic algorithm designed to predict HIV-1 tropism takes into account only the net 
charge of amino acids at two key residues located within the V3 loop, amino acids at 
positions 11 and 25. The most widely used is the 11/25 rule which focuses on identifying 
sequence patterns within the V3 loop. Predictions using the “11/25 charge rule” are 
relatively satisfactory.  
19. Correlation between phenotypic and bioinformatics tools in 
determining HIV coreceptor use  
Evaluation of the performances of genotypic tools to predict HIV-1 tropism has been 
investigated. Paired genotypic and phenotypic determination of HIV-1 coreceptor usage has 
been performed to assess several genotypic approaches for detecting CXCR4-using and 
CCR5-using viruses in a clinical setting. Excellent correlations between HIV-1 V3 genotype 
and phenotype have been observed. Overall, the accuracy of the bioinformatics tools to 
detect CXCR4-using virus was similar for ES Trofile and Trofile. However, the negative 
predictive values for genotypic tools with ES Trofile were slightly higher than they were 
with Trofile. The accuracy of genotypic algorithms for detecting CXCR4-using viruses is 
high when using Trofile as the reference. The concordance with ES Trofile is better with 
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higher CD4 cell counts and non-exposure to antiretroviral therapy. The global concordance 
between genotypic and phenotypic data is 91% with the rule combining the amino-acid 
residues at positions 11/25 and V3 net charge. Gaining a better understanding of the output 
of these assays and correlating them with clinical progression and therapy response will 
provide some indication on how both genotype-based and phenotypic assays for 
determining HIV coreceptor usage can be improved. Deep V3 sequencing is a promising 
tool for identifying treatment-experienced individuals who could benefit from CCR5-
antagonist-containing regimens. 
20. Challenges of genotypic methods 
Genotypic predictions are relatively satisfactory but because not all determinants of 
coreceptor usage lie within the V3 loop, the region employed by most current predictors, 
causing occasional disagreements. Accurate prediction is also complicated by the fact that 
the V3-C4 region of the env gene, which has the greatest influence on tropism, also has a 
relatively high rate of diversity such that the sensitivity drops with uncloned sequences and 
HIV-1 non-B subtypes. Since non-B subtypes show a wide genetic variability in the V3 
region and taking cognisance that X4 viruses might be more prevalent in some subtypes 
than others, there is an urgent need to know the reliability of genotypic tools for inferring 
HIV-1 tropism in non-B subtypes, especially in regions where these HIV-1 variants are quite 
prevalent and may soon have access to CCR5 antagonists. Moreover, technical limitations to 
the generation of unambiguous DNA sequences from the HIV-1 env region that has 
insertions and deletions may interfere with the generation of clean and clear 
electropherograms thereby interfering with a predictive determination of tropism in a 
significant portion of patients’ samples. Prospective studies are needed to firmly establish 
the clinical usefulness of genotypic tropism determination. Further research is also 
warranted regarding the need for specific genetic characteristics of dual/mixed-tropic HIV-1 
strains which also exist in a significant proportion of patients.  
21. HIV-1 coreceptor usage and genetic subtypes 
There are remarkable differences in the prevalence of CXCR4-using variants among 
different HIV-1 genetic subtypes and circulating recombinant forms (CRFs). Since CXCR4-
using variants emerge after an accumulation of mutations, the different prevalence observed 
may reflect the same phenomenon at the population level. Infection with subtype-C 
accounts for over half of the worldwide HIV-1 epidemics and is rapidly expanding in 
Southern Africa, South East Asia and India. Studies have shown this rapidly expanding 
subtype C isolates almost exclusively use the CCR5 coreceptor, with CXCR4 usage being 
rarely observed. Some authors argue that the predominant usage of CCR5 by HIV-1 subtype 
C isolates is more due to sampling artifacts rather than any fundamental biological 
properties of these viruses. Unique to subtype C is the determinant of coreceptor usage, the 
V3 regions which has been shown to be highly conserved and have a low overall positive 
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charge, which is consistent with the NSI phenotypes compared to other subtypes. Moreover, 
this atypical property of the subtype C envelope glycoproteins might be the reason behind 
the rapid expansion of the virus being currently observed. In view of this, there is need for 
intervention strategies that are subtype specific to curb this pandemic tailor designed for 
use in areas where subtype C viruses predominate. R5-using viruses have also been found 
to be more common in subtype A than subtype D HIV-1 infections. The emergence of X4 
viruses occurs very early among subtype D-infected individuals. More so, a high 
proportion of subtype D infections have been shown to display D/M tropism throughout 
the course of disease. An inverse skewing in coreceptor usage, with an increased presence 
of CXCR4-using strains, has instead been reported for subtype-D HIV-1. This observation 
is consistent with the faster pace of disease progression reported for subtype-D infection 
both in Africa and abroad. An increased rate of CXCR4 usage has also been reported for 
CRF AE isolates common in South East Asia. There are proposals to the effect that the 
increase in prevalence of CXCR4-using HIV-1 variants increases with the age of the 
subtype epidemic. Indeed recent phylogenetic studies suggest that the proportion of 
patients with detectable CXCR4 using HIV-1 variants varies with subtype D having the 
highest CXCR4 switch rate being the oldest whilst subtype C with the lowest CXCR4 
switch rate being the youngest. Subtype B predominant in North America and Europe has 
demonstrated that CXCR4 coreceptor usage increases with time following infection with or 
without concurrent use of R5 in 50% of HIV-1 infected individuals. The HIV-1 subtype-B 
epidemic has an intermediate pattern, both in terms of age and prevalence of CXCR4-using 
HIV-1 variants. This assumption is highly speculative and not supported by all the data 
available at present. However, if confirmed it would imply that all the subtype epidemics 
are evolving towards a higher prevalence of CXCR4-using HIV-1 variants although it is 
plausible that each epidemic would reach a point of equilibrium beyond which such 
prevalence will not further increase.  
22. HIV coreceptor usage and compartmentalization 
Compartmentalization is the occurrence of distinct yet phylogenetically related HIV-1 
phenotypes or genotypes within different anatomic sites, an observation common amongst 
both treated and untreated individuals. Differences in selective pressures may shape the 
distinct viral populations in different compartments. Anatomic compartmentalization of 
HIV coreceptor usage variants has been described in diverse tissues including in blood, 
lungs, brain, central nervous system, breast milk and genital tract. Studies have shown that 
the distribution of R5 and CXCR4-using variants differ in different blood compartments. 
Higher prevalence of predicted CXCR4-using variants in PBMC than in plasma has been 
reported. The limited compartmentalization and the clonal amplification of evolving 
functional viruses in milk indicate continual seeding of the mammary gland by blood virus 
variants, followed by transient local replication of these variants in the breast 
compartment. 
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Gender studies have demonstrated different viral variants between genital tract and blood 
for both women and men. Differences in genetic strains between blood- and semen-derived 
HIV isolates within the same individual have been documented. Male genital tract tissues 
such as the prostate, seminal vesicles, and epididymis which serve as sites of viral 
replication have been found to develop distinct, compartment-specific HIV strains in 
response to these local selective pressures. Studies seeking to determine chemokine receptor 
preference for all sequences derived from patients with compartmentalized virus to 
determine if seminal tropism correlated with altered coreceptor usage have shown a trend 
towards reduced CXCR4 usage in the male genital tract.  
Other environmental factors such as sexually transmitted infections (STIs) have been also 
shown to exert selective pressures. Genital inflammation can stimulate the expression of R5 
receptors dramatically, conferring a selective advantage on R5 virus in the genital tract of 
women with STIs. A history of intravenous drug use (IDU) among women has been shown 
to correlate with larger proportions of X4 strains in plasma relative to those without an IDU 
record. Quantifying the proportion of R5 and X4 viruses in each compartment has been 
found to vary significantly between them. Thus, the proportion of X4 strains in one 
compartment does not necessarily reflect coreceptor usage in the other suggesting that 
measuring coreceptor usage in say the genital tract and blood may aid in effective 
monitoring of disease progression and response to therapy as efficiencies of antiretroviral 
drug penetration has also been found to differ with compartments. Hence, there is need for 
compartment specific treatment outcome monitoring of patients and also the most 
appropriate choice of patient material for the determination of HIV-1 coreceptor usage 
remains to be established.  
23. Chemokine receptors and viral entry into host cells  
The entry of HIV into cells is critically dependent on the sequential interaction of the viral 
envelope with two cell-surface receptors, the CD4 glycoprotein and CCR5 or CXCR4. The 
evolutionary choice of HIV of exploiting chemokine receptors as entry gateways has 
established a tight biological bond between HIV and the chemokine system, making the 
respective natural ligands of these receptors potent viral inhibitors. Entry into target cells by 
HIV occurs by a multi-step process that culminates with the fusion of viral and cellular 
membrane as shown in figure 3 below. Many enveloped viruses including HIV possess a 
fusion protein in their envelopes which confers the ability of the virion to fuse with the host 
cell membrane and thus allowing entry of the infectious genomic material into the cell 
cytoplasm. Receptor interactions then trigger gp41 to promote membrane fusion. This 
reaction is thought to involve extension of the gp41 subunit to allow insertion of its N-
terminal ‘fusion peptide’ into the target cell membrane, followed by refolding the prefusion 
intermediate into an energetically favorable six-helix bundle that brings the two membranes 
together so that fusion can occur. During replication of the virus, expression of the fusion 
protein on the cell membrane can result in the fusion of neighbouring cells forming multi-
nucleate cells or syncytia. 
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Figure 3. Interaction between HIV-1 and the cell surface Molecules, adopted from Levy J, 1996 
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24. Coreceptor usage and HIV-1 transmission 
Irrespective of the transmission route or HIV-1 subtype, R5 viruses are preferentially 
transmitted in both horizontal and vertical transmission events except for subtype D. HIV 
transmission via breastfeeding accounts for a considerable proportion of infant HIV 
acquisition. However, no conclusive evidence has been provided to indicate that CXCR4-
using strains are less able or unable to sustain mucosal transmission. For example simian 
chimeric immunodeficiency viruses (SHIV) bearing an X4 HIV-1 envelope can be readily 
transmitted via the mucosal route in macaques, and have widely been used as a reference 
model. Another important element that is rarely taken into consideration in the HIV-1 
transmission equation is the transmitter bias which suggests that individuals with 
replicating CXCR4- using viruses are more likely to be in a more advanced stage of their 
disease progression and hence are more likely to be too ill to engage in risky sexual 
behavior. Majority of transmissions occur from asymptomatic individuals who generally 
harbor R5 variants. Consequently, the transmission of CXCR4-using variants may in fact be 
more frequent than it appears, albeit underestimated due to late sampling. Although 
primary infection with CXCR4-using HIV-1 strains is believed to be a rare event, mixed 
R5/X4 primary infections have been documented. Vertical transmission of dual tropic HIV-1 
has also been demonstrated. Genotypic characteristics of HIV-1 V3 loop that are 
preferentially vertically transmitted for different subtypes remain unclear yet this 
information is critical for the development of effective transmission preventive strategies. At 
least for HIV-1 subtype B maternal viral phenotype can be predictive of the newborn’s viral 
phenotype whilst the dual R5X4 phenotype is predominantly lost during vertical 
transmission. Antenatal HIV-1 subtype C coreceptor usage is generally preserved in vertical 
transmission and can be predictive of the newborn’s viral genotype. 
25. Co receptor usage and HIV Disease progression  
Coreceptor usage is a marker for disease progression. There is a continued evolution in viral 
coreceptor usage in vivo, resulting in a broad range of coreceptor affinities within the HIV-1 
quasi-species. Discriminating between these and other alternatives is central to increasing 
our understanding of the fundamental pathogenic processes involved in HIV-1 infection.  
26. CCR5 HIV-1 variants 
During the asymptomatic phase of HIV-1 infection a homogeneous R5 virus population is 
commonly present that can replicate efficiently in both T cells and macrophages. The early 
stages of HIV infection and the latency phase are characterised by CCR5 coreceptor using 
viral variants which are less virulent, non-syncytium-inducing and are associated with 
reduced progression to AIDS. A significant proportion of patients progresses to full-blown 
AIDS without experiencing an overt switch to CXCR4 usage, indicating that CCR5 usage 
remains a critical coreceptor throughout the course of HIV infection. This has been 
supported by the observation that the ability of R5 isolates to replicate in macrophages is 
progressively reduced during the course of infection, resulting in a predominantly T-cell 
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tropic R5 HIV-1 quasi-species even before the progression to AIDS. However, studies have 
shown that these late stage homogeneous CCR5 isolates are more pathogenic than the 
earlier isolates. In line with this observation is the ability of late-stage CCR5-restricted HIV-1 
variants to use chimeric coreceptors where some parts of CCR5 would have been replaced 
with segments of CXCR4 (R5 broad), whilst early CCR5-using HIV-1 variants are restricted 
to the use of wild-type CCR5 (R5 narrow). This in vivo evolution of CCR5-restricted HIV-1 in 
humans is similar to that observed in non-human primates infected with SIV, which never 
acquires CXCR4 usage even though its pathogenicity increases during the late disease 
stages. This evolution is accompanied by improved coreceptor-binding affinity, which in 
turn is reflected in decreasing sensitivities of R5 variants to inhibition by CCR5-binding 
chemokines and small- molecule CCR5 antagonists. 
27. Co-existence of R5 and CXCR4- HIV-1 variants 
Some HIV-1 variants can use either coreceptor hence they are termed dual/mixed (DM)-
tropic. These have been detected in all stages of infection although they are more common in 
infections of longer duration, with lower CD4+ cell counts and higher viral loads. Such 
strains produce gp120 molecules capable of recognizing the CXCR4 protein on CD4-bearing T-
cells. During this phase HIV-1 may infect both macrophages and T-cells. Still later, the bulk of 
the viral population may switch it's preference to the CXCR4 receptor and become T-tropic. T-
tropic viruses readily destroy infected T-cells, contributing to the collapse of the immune 
system and the onset of AIDS. Evidence suggests that the evolutionary changes in the V3 
loop involved in the coreceptor-usage switch are gradual with dual coreceptor usage (R5X4) 
representing an intermediate transitional phase. Once established the DM–tropic viruses 
have been shown to develop the optimal fitness to predominate during the transition phase, 
although they may eventually be outcompeted by HIV-1 variants with a pure X4 phenotype.  
28. X4 variants 
Following years of chronic HIV infection X4 using strains emerge although this 
phenomenon is not consistently observed in all patients progressing to AIDS. This switch of 
coreceptor usage has been shown to be associated with accelerated decrease in CD4 cells 
and hence it could be an important determinant of HIV pathogenesis and disease 
progression. The emergence of X4 variants has also been shown to coincide with disease 
progression and has been associated with longer duration of antiretroviral treatment 
including higher risk of death. The mechanism by which X4 viruses are associated with 
accelerated disease progression has never been properly elucidated although one theory 
proposes that R5-viruses lose their fitness with time, showing an abrupt decline in their 
ability to use CCR5 coreceptors and to infect cell lines with low CCR5 expression, 
demonstrating an increased susceptibility to CCR5 inhibitors consequently creating a pro-
X4-virus environment. It has also been postulated that the decline of the host immune 
system associated with clinical AIDS may allow X4 viruses to evolve and replicate freely in 
late-stage infection. Furthermore, it has also been reported that disease progression among 
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individuals infected with subtypes D and C is faster than in those infected with subtypes A 
and A/G in Africa and that subtype D infection leads to faster rates of CD4 cell decline and 
subsequent virological failure compared to infection with subtype B and other non-subtype 
B HIV strains in England. 
29. Host coreceptor genes & insights on resistance to HIV infection 
A disproportionate transmission and distribution of HIV epidemic in the world has been 
observed with alarming rates in Sub Saharan Africa (SSA). Currently there is very little 
explanation for this observation of differences in susceptibility to HIV infection which could 
among other factors be attributable to variation in host genetics. Host genetic factors, 
including some polymorphisms in chemokine receptors and chemokine genes have been 
identified as having an impact on both HIV-1 infection and disease progression to death. 
Scientists have observed that despite multiple or repeated unprotected sexual exposures to 
HIV-1, some individuals remain HIV sero-negative. More so the discovery of long-term non-
progressors (LTNP) in HIV infection prompted further investigations to ascertain the role of 
host genetic factors in the progression of HIV infection to AIDS. Polymorphisms in these 
human chemokine receptor genes will therefore affect the evolution of HIV-1. 
30. CCR5 gene mutation 
Analysis of blood samples from infected persons and the repeatedly exposed but somehow 
uninfected have shown specific molecular differences within the coding and regulatory 
regions of chemokine receptors and coreceptors genes. There is a deletion of 32 base pairs 
from the coding region of CCR5 gene in the second ECL. In these individuals the 32-base 
deletion in the CCR5 gene results in a frame shift and truncation of the normal CCR5 
protein which renders them uninfectable after exposure to CCR5 tropic HIV viruses. This 
aberrant protein has been associated with protection against HIV-1 infection in people who 
are homozygous for mutant genotypes. Thus individuals resistant to HIV infection inherit 
two mutated copies of the dysfunctional gene for CCR5 from either parent. Without 
functional coreceptors, HIV is not able to enter immune cells. Despite the strong protective 
effect conferred by congenital CCR5 deficiencies, a handful of infected CCR5-Δ32 
homozygotes have been reported, all invariably harboring CXCR4- dependent HIV-1 
strains. The rare homozygous individuals that got infected by HIV have been shown to be 
through CXCR4 coreceptor mediated entry only. Interestingly it has been found that in such 
homozygous conditions there is no evidence of health/phenotypic impairment caused by the 
absence of functional CCR5 coreceptors. However, HIV-infected individuals who would 
have inherited a copy of the defective CCR5 gene from only one parent, heterozygotes for a 
Δ32 deletion (CCR5-wt/Δ32) are not protected against HIV-1 infection but are associated 
with a much slow progression to AIDS relative to those with two normal copies of the gene. 
Heterozygous individuals have lower plasma HIV RNA levels in the early years of 
infection, which gives them a medical advantage of delaying disease progression. Since 
these mutations do not account for all cases of resistance to HIV infection, scientists are 
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looking for other possible host factors, including genetic defects involving other coreceptors. 
It was this protective property of CCR5∆32 against HIV infection that has prompted 
pharmaceutical companies to develop a CCR5 antagonist for clinical use in the treatment of 
HIV/AIDS. Studies have shown that inhibition of CCR5 coreceptor seems not to cause 
significant clinical harmful consequences yet surprising to date there has not been any 
description of natural genetic alteration in CXCR4 human gene, suggestive that mutations in 
this gene are incompatible with life.  
31. Epidemiology of CCR5∆32 gene 
A general North to South downhill gradient in CCR5∆32 gene frequency has been observed. 
The highest frequency has been found in Northern and North-eastern Europe especially 
amongst the Finnish and Swedish populations. Data confirm the high frequency of CCR5-
Delta 32 among northern European Caucasians, a gene frequency declining across Europe 
and Asia reflecting recent population admixture. The virtual absence of CCR5-Delta 32 
deletion among native Africans, East Asians, and American-Indians is suggestive that the 
mutation arose in northern Europe in response to selective pressures due to other factors 
including infection epidemics. The CCR5∆32 has a prevalence rate of between 20-35% 
among the Jewish population. In Africa studies indicated that the allelic frequency of 
CCR5∆32 mutation is 0.1% in the black South African population.  
32. CCR2 –V641 mutation 
A CCR2 –V641 mutation from a conservative valine to isoleucine substitution in the 
transmembrane region has also been associated with some protective effects against HIV 
infection and reduction in progression of HIV to AIDS. The protective effect of CCR2 –V641 
is believed is to be through regulation linkage disequilibrium in the regulatory region or 
promoter region of this gene. CCR2-V64I is common among Africans, yet this race is one of 
the most affected populations by the HIV pandemic. Hence, the protective effect of CCR2 –
V641 against HIV infection remains controversial. Despite the availability of evidence 
linking some host genetic factors to protection against HIV infection, very little information 
is available regarding the role of CCR5-∆32 and CCR2-V64I polymorphism on HIV 
transmission. 
33. Coreceptor antagonists and antiretroviral therapy 
To successfully infect an immune cell HIV env gp 120 has to interact with the host cellular 
receptor CD4 and either a CCR5 or CXCR4. Both coreceptors are recognized as novel targets 
for anti-HIV-therapy consequently resulting in the development of a new class of 
antiretroviral drugs called coreceptor antagonists or blockers. Blocking these coreceptors 
would protect the host cell from viral entry and would reduce the viral transmission and 
pathogenesis. Interestingly coreceptor antagonists differ from the other antiretroviral agents 
that target HIV proteins in the sense that they bind and inhibit receptors encoded by the 
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host itself. Besides blocking replication of the virus in other cells, coreceptor antagonists 
may reduce the decline of immune system through other ways. It is known that HIV-1 env 
glycoproteins may trigger autophagy in uninfected CD4 positive T cells, leading to their 
apoptosis, and consequently increasing immune decline. These cells need to present, among 
other things, a CXCR4 coreceptor in their surface. The blockage of the interaction between 
glycoproteins and the coreceptor of uninfected cells could help to avoid immune 
impairment. CCR5 antagonists design and development are a step ahead relative to their 
CXCR4 counterparts. This unique new class of drugs not only increases the alternative 
therapeutic options for HIV treatment but also maximizes potency, minimizes toxicity and 
reduces the risk of drug resistance development. Range of coreceptor antagonists discovered 
to date includes modified chemokines monoclonal antibodies, peptides and small organic 
molecules.  
34. Mechanism of action of coreceptor antagonists 
Coreceptor antagonists’ antiviral properties are related to their ability to internalize the 
receptor, preventing it from being expressed on the cell surface thereby avoiding viral 
replication by reducing coreceptors availability to bind to HIV glycoproteins. 
 
Figure 4. Mode of Action of Coreceptor antagonists  
35. Coreceptor antagonists in development 
35.1. Modified chemokines 
Modified chemokines include RANTES, a natural chemokine ligand for CCR5 manufactured by 
RANTES engineering technology including other novel agents that have not been very 
successful and their future remains uncertain. Other possible antagonists are zinc finger 
nucleases that cause mutagenesis in the CCR5 gene by binding and cleaving the gene, 
producing abnormal proteins. Zinc fingers, along with RNA interference, ribozymes, intrakines, 
and intrabodies are HIV-1 vector-delivered genetic disruption mechanisms that target HIV-1 
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chemokine receptors. Although chemokines or derivative-molecules could be exploited as 
therapeutic agents against HIV, the risk of inducing inflammatory side-effects or of interfering 
with the physiology of the homeostatic chemokine system represents a potential limitation. 
36. Monoclonal antibodies as coreceptor antagonists 
Another type of coreceptor antagonists are monoclonal antibodies. Examples of such agents are 
CCR5mAb004 of Human Genome Sciences (Rockville, MD, USA) and PRO 140 of Progenics 
Pharmaceuticals (Tarrytown, NY, USA). They are both mouse-derived but humanized 
monoclonal antibodies capable of blocking CCR5 without activating the signal transduction 
pathways. In phase I clinical trials CCR5mAb004 has been shown to be safe and well tolerated.  
37. Small molecule CXR4 chemokine receptor antagonists 
AMD3100 is a small-molecule CXCR4 antagonist with activity against X4 viruses’ in vitro and 
antiviral activity in vivo, although it is no longer being pursued clinically because of 
pharmacology and toxicology considerations. More examples of small molecule chemokine 
receptor antagonists of CXCR4 coreceptor include AMD11070/ AMD070, AMD3465, ALX40-
4C, T22, T134 and T140. AMD11070 is known to specifically inhibit CXCR4 in a reversible way. 
Other CXCR4 selective inhibitor is AMD3100 from AnorMED. AMD3100 is highly specific for 
CXCR4 that blocks replication of X4 strains. However, clinical trials of AMD3100 have been 
stopped due to side effects of cardiotoxicity. A relatively safer derivative of AMD3100 known 
as AMD070 is currently undergoing clinical trials. Previously AMD3100 has proved to be a 
useful tool to probe interactions between env proteins and CXCR4 which is important to 
identify pathways by which HIV-1 may become resistant to this class of antiviral agents. To 
date none of CXCR4 blockers has successfully proceeded into clinical practice due to their 
severe side effects. Generally, CXCR4-based blocking agents are less attractive due to the 
crucial role of CXCR4 in many biological processes. However, agents that aim at down-
modulating CXCR4 expression may provide some benefits to HIV-positive patients. 
Antagonism of CXCR4 has been shown to significantly improve survival from lethal infection 
through enhanced intraparenchymal migration of West Nile Virus-specific CD8+ T cells within 
the brain, leading to reduced viral loads and decreased immunopathology at affected sites. 
38. Small-molecule CCR5 antagonists 
The CCR5 antagonists act on a wide spectrum of viruses with affinity or tropism for this 
receptor. They are absorbed orally and have powerful antiviral activity through interaction 
with amino acids from the pocket formed by the transmembrane (TM) domains of CCR5. 
Mechanism of action is through allosteric effects, altering extracellular CCR5 conformation 
after binding to a hydrophobic pocket of CCR5, formed by transmembrane helices. Mutations 
within transmembrane domains are associated with impaired activity. Small molecule CCR5 
antagonists such as maraviroc, vicriviroc, aplaviroc, TAK-779, and TAK-220) have been 
found to fit in the same binding pocket. Other small-molecule CCR5 antagonists include: 
 Immunodeficiency 254 
Tak-652, spirodiketopiperazine derivatives such as E913 and SCH-C/SCH-351125. 
Spirodiketopiperazine derivatives have been associated with severe hepatotoxicity, leading to 
the cancellation of their development. SCH351125 or SCH-C was the first CCR5 antagonist to 
enter clinical efficacy studies but has been dropped out due to variable antiviral effect and 
provocation of prolonged QTc interval. To counter these setbacks Vicriviroc was developed 
which was much more potent than SCH-C, safer and better oral bioavailability. 
Two agents, maraviroc and vicriviroc, are the agents within this family that have passed the 
final stages of clinical development. These agents have their scientific names ending in “–
viroc”, to denote their action of “viral receptor occupancy”. Since these drugs show activity 
against R5 viruses only, viral tropism testing should be made before their prescription and 
eventually during treatment in order to exclude the presence of X4 viruses. They are less 
expensive to produce and have good oral bioavailability. Their half maximal inhibitory 
concentrations (IC50) are in the nanomolar ranges.  
39. Maraviroc  
A success story has been the introduction CCR5 antagonist, Maraviroc, trade name Selzentry 
or Celsentri into clinical practice. Maraviroc is a non-competitive CCR5 antagonist that 
selectively binds to the human CCR5, present on the cell membrane, preventing the interaction 
with HIV-1 env gp 120. CCR5 is necessary for CCR5-tropic HIV-1 to enter cells. It is 
metabolized in the liver. Drug plasma concentrations are likely to be increased in patients with 
hepatic impairment. Route of metabolism is through Cytochrome P450 3A4 (CYP3A). The 
drug has shown potent activity against multidrug-resistance CCR5-tropic HIV-1 strains. It has 
antiviral activity in vitro against CCR5 tropic HIV-1 isolates from various subtypes. However, 
Maraviroc has no activity against CXCR4-tropic and dual tropic HIV-1. It has been found to be 
effective, efficient and safe to use in combination with other antiretroviral agents such as with 
lopinavir/ritonavir plus efavirenz or saquinavir/ritonavir plus efavirenz in adult patients with 
exclusive CCR5 tropic HIV-1 isolates. Maraviroc was developed by Pfizer Inc. (Kent, UK).  
 
Figure 5. Structure of Maraviroc adopted from chemicalbook.com 
Maraviroc inhibit CCR5 binding and signaling at nanomolar (nM) concentrations (IC90 of 2 
nM). It is well tolerated with most common mild to moderate side-effects including 
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headache, asthenia, dizziness, gingivitis and nausea. It is known that before starting on a 
coreceptor antagonist, patients need to determine their viral tropism. The introduction of the 
CCR5 antagonist, maraviroc for HIV-1 therapy has increased the research interest in the 
epidemiology of tropism and its relationship with HIV-1 subtype. A greater understanding 
of the tropism of non-B subtypes is key for the optimal use of CCR5 antagonists in the 
treatment of these infections in the developing world and HIV-1 prevention strategies. 
There is no food effect as it can be taken with or without food and can be stored at room 
temperature. Hence it is very suitable for resource poor settings which also bear the brunt of 
the HIV scourge with predominant R5 variants.  
 
Figure 6. Mode of action of maraviroc, adopted from Qian K, 2008.  
40. Challenges of CCR5 antagonists 
The CCR5-to-CXCR4 switch represents a concern because while CCR5 inhibitors suppress 
R5 viruses they may allow the emergence of CXCR4-tropic viruses. Efforts to develop HIV 
entry inhibitors are hampered by problems associated with rapid evolution of the virus, 
leading to drug resistance. Blocking only one of the pathways for HIV entry into cells has 
resulted in the opening of the other pathways potentially accelerating disease progression 
by promoting the evolution of more virulent CXCR4-dependent variants. In this view, 
AnorMED Company has announced the discovery and development of a joint CXCR4/CCR5 
antagonist although little is known about the binding mechanism at this time. 
41. Future of coreceptor antagonists  
There have been speculations that new, safe and effective chemokine receptor inhibitors 
should facilitate CCR5 and CXCR4 internalization independent of the cellular signaling. The 
most anticipated eventual combination of CXCR4 and CCR5 inhibitors would be beneficial, 
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since selective pressure could direct the virus to use less productive coreceptors, avoiding 
the progression of the disease. In addition leveraging new technologies capable of detecting 
low-level minority species may provide the most significant advances in ensuring that 
individuals with low levels of dual/mixed tropic virus are not inadvertently prescribed 
CCR5 antagonists.  
Author details 
Kerina Duri 
University of Zimbabwe, College of Health Sciences, Department of Immunology, Harare, Zimbabwe 
42. References 
[1] Asjo B, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K, et al. 
Replicative capacity of human immunodeficiency virus from patients with varying 
severity of HIV infection Lancet 1986 Sep 20;2(8508):660-2. 
[2] Hoffman TL and Doms RW (1999). HIV-1 envelope determinants for cell tropism and 
chemokine receptor use. Mol Membr Biol 16: 57-65. 
[3] Sundaravaradan V, Das SR, Ramakrishnan R, Sehgal S, Gopalan S, Ahmad N and 
Jameel S (2007). The role of HIV-1 subtype C V3 to C5 region in viral entry, coreceptor 
utilization and replication efficiency in primary T- lymphocytes and monocyte derived 
macrophages. Virology Journal, 4:126 
[4] Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C and Katzenstein 
DA (2003). High frequency of syncytium–inducing and CXCR4–Tropic viruses among 
human Immunodeficiency virus type 1 subtype C infected patients receiving 
antiretroviral treatment. J. Virol 77(13): 7682-7688. 
[5] Moyle GJ, Wildfire A Mandalia S. (2005) Epidemiology and predictive factors for 
chemokine receptor use in HIV-1 infection. J. Infect Dis 191: 866-872. 
[6] Casper CHE, Clevestig P, Carlenor E, Leitner T, Anzen B, Lidman K, Belfrage E, Albert 
J, Bohlin AB, Naver L, Lindgren S, Fenyo EM and Ehrnst AC (2002). Link between the 
X4 phenotype in Human Immunodeficiency Virus Type 1 infected mothers and their 
children, despite the early presence of R5 in the child. JID 186: 914-921 
[7] Regoes RR and Bonhoeffer S (2005) The HIV coreceptor switch: a population dynamics 
perspective. Trends Microbiol.13: 269-277. 
[8] Huang W, Toma J, Stawiski E, Frasen S, Wrin T, Parkin N, Whitcomb JM, Coakley E, 
Hecht FM, Deeks SG, Gandhi RT, Eshleman SH and Petropoulos CJ (2009). 
Characterisation of Human Immunodeficiency virus type 1 population containing 
CXCR4- using variants from recently infected individuals. AIDS Research and Human 
Retroviruses 25(8): 795-802. 
[9] Huang W, Eshleman SH, Toma J, Stawiski E, Whitcomb JM (2007). Coreceptor tropism 
in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 
tropism and heterogeneous composition of viral population. J. Virol 81: 7885-7893). 
 
Coreceptor Usage in HIV Infection 257 
[10] Sayana and Homayoon Khanlou, (2008). Maraviroc: a new CCR5 antagonistic. Expert 
Rev. Anti Infect Ther 7(1): 9-19. 
[11] Hunt JS and Romanelli F (2009). Maraviroc, a CCR5 coreceptor antagonist that blocks 
entry of Human Immunodeficiency Virus type 1. Pharmacotherapy 29(3):295-304  
[12] Delobel P, Nugeyre MT, Cazabat M, Pasquier C, Marchou B, Massip P (2007). 
Population based sequencing of the V3 region of env for predicting the coreceptor usage 
of human immunodeficiency virus type I quasispecies. J Clin Microbiol: 45: 1572-1580. 
[13] Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Saune K, Cuzin L, 
Marchou B, Massip P and Izopet J (2008). Correlation between genotype predictions 
based V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22: F11-F16. 
[14] Jensen MA, Coetzer M, van’t Wout AB, Morris L. and Mullins JI (2006). A reliable 
phenotype predictor for Human Immunodeficiency virus type 1 subtype C based on 
envelope v3 sequences. J of Virol: 80: 4698-4704.  
[15] Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors: central to 
understanding the transmission and pathogenesis of human Immunodeficiency virus 
type 1 infection. AIDS Res Hum Retroviruses 2004: 20: 111-126. 
[16] Clerici M, Butto S. and Lukwiya M (2000). Immune activation in Africa is 
environmentally –driven and is associated with up-regulation of CCR5. Italian-
Ugandan AIDS Project. AIDS 14: 2083-2092. 
[17] Poveda E, Briz V, de Mendoza C, Benito JM, Corral A, Zahonero N, Lozano S Gonzalez-
Lahoz and Soriano V (2007). Prevalence of X4 tropic HIV-1 variants in patients with 
differences in disease stage and exposure to antiretroviral therapy. J Med virology 79: 
1040-1049. 
[18] Huang W, Eshleman SH, Toma J, Stawiski E, Whitcomb JM, Jackson JB, Guay L, 
Musoke P, Parkin N and Petropoulos CJ (2009). Vertical transmission of X4 tropic and 
dual tropic HIV-1 in five Ugandan mother-infant pairs. AIDS: 23 (14): 1903-1908. 
[19] Fitzgibbon JE, Gaur S, Gavai M, Gregory P, Frenkel LD, John JF Jr. (1998) Effect of the 
HIV-1 syncytium- inducing phenotype on disease stage in vertically–infected children. 
J. Med Virol 55: 56-63. 
[20] Coetzer M, Cilliers T, Ping L, Swanstrom R and Morris L (2006) Genetic characteristics 
of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology 
356: 95-105. 
[21] Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, Paxton WA (2004). 
Intra-patient alteration in the human immunodeficiency virus type 1 gp120 V1V2 and 
V3 regions differentially modulate coreceptor usage, virus inhibition by CC7CXC 
chemokines, soluble CD4 and b12 and 2G12 monoclonal antibodies. J Virol 78(1): 524-
530. 
[22] Mild M, Kvist A, Esbjornsson J, Karlsson I Fenyo EM and Medstrand P (2009). 
Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non 
switch (R5 tropic only) HIV-1 populations during infection. Infection, Genetic & 
evolution MEEGID- 584: 1-9  
[23] Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, 
Nomiyama H, Schall TJ, Yoshie O (November 1997). "Identification and molecular 
 Immunodeficiency 258 
characterization of fractalkine receptor CX3CR1, which mediates both leukocyte 
migration and adhesion". Cell 91 (4): 521–30  
[24] Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, 
Nomiyama H, Schall TJ, Yoshie O (November 1997). "Identification and molecular 
characterization of fractalkine receptor CX3CR1, which mediates both leukocyte 
migration and adhesion". Cell 91 (4): 521–30 
[25] Duri K, Soko W, Gumbo F, Kristiansen K, Mapingure M, Stray-Pedersen B, Muller, F 
and the BHAMC Group. ARHR 2010; 27(4):411-419.Genotypic analysis of Human 
Immunodeficiency Virus type 1 (HIV-1) env V3 loop sequences: Bioinformatics 
prediction of coreceptor usage among 28 infected mother-infant pairs in a drug-naive 
population.  
[26] Duri K, Gumbo FZ, Kristiansen KI, Mapingure MP, Munjoma M, Rusakaniko S, 
Chirenje MZ, Stray-Pedersen B and Muller F. ARHR 2011 Dec [Epub ahead of 
print].Phylogenetic Analysis of Human Immunodeficiency Virus type 1 (HIV-1) 
Subtype C Env gp 120 sequences among four drug naïve families following subsequent 
heterosexual and vertical transmissions.  
[27] Pillai SK, Good B, Pond SK, Wong JK, Strain MC, Richman DD, et al. Semen-specific 
genetic characteristics of human immunodeficiency virus type 1 env. J Virol 2005 
Feb;79(3):1734-42. 
[28] Typical chemokine receptor structure showing seven transmembrane domains and a 
characteristic "DRY" motif in the second intracellular domain. In Wikipedia, the free 
encyclopedia, vol. 29 KB; 2006. 
[29] Mild M, Esbjornsson J, Fenyo EM, Medstrand P: Frequent intra-patient recombination 
between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for 
coreceptor switch. J Virol 2007, 81: 3369-3376. 
[30]  Qian K, Morris-Natschke SL, Lee KH: HIV entry inhibitors and their potential in HIV 
therapy. Med Res Rev2008. 
[31] Salazar-Gonzalez JF, Salazar MG, Learn GH, Fouda GG, Kang HH, Mahlokozera T, et 
al. Origin and evolution of HIV-1 in breast milk determined by single-genome 
amplification and sequencing. J Virol 2011 Mar;85(6):2751-63. 
